/PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—

/PRNewswire/ -- 随着代谢功能障碍相关脂肪性肝炎（MASH）成为肝衰竭最危险且未被充分诊断的诱因之一——全球影响超过2.5亿人——

Echosens

回声传感

, the leader in non-invasive liver diagnostics, and

，非侵入性肝脏诊断领域的领导者，以及

Boehringer Ingelheim

勃林格殷格翰

, a global biopharmaceutical company, today announced an expansion of their long-standing partnership to change the trajectory of the disease by moving beyond clinical trials to focus on early detection, diagnosis, and access to care.

，一家全球生物制药公司，今天宣布扩大其长期合作关系，通过超越临床试验，专注于早期检测、诊断和获得治疗，来改变疾病的轨迹。

Courtesy of Boehringer Ingelheim

礼来自勃林格殷格翰

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next phase of partnership will include:

通过结合其诊断和治疗专业知识，Echosens 和勃林格殷格翰旨在帮助缩小在认知、真实世界证据和临床应用方面的持续差距。此合作的下一阶段将包括：

Raising awareness of MASH

提高对MASH的认识

among patients, healthcare professionals, and policymakers about the urgent need for early screening and diagnosis.

在患者、医疗专业人员和政策制定者之间，关于早期筛查和诊断的迫切需求。

Encouraging the adoption of streamlined care pathways

鼓励采用简化的护理路径

by fostering collaboration across healthcare organizations and medical specialties.

通过促进跨医疗机构和医学专业的合作。

Expanding awareness and access to non-invasive technologies (NITs)

扩大对非侵入性技术 (NIT) 的认识和获取途径

, including scientific collaborations to generate evidence relating to NITs in the care of people living with MASH.

，包括科学合作以生成与NITs在MASH患者护理中相关的证据。

'For too long, serious liver diseases like MASH have gone under the radar—but with MASH rates soaring alongside the global obesity epidemic, it's time to tackle liver disease head on,' said Sandy Sommer, Head of the Therapeutic Area for Cardiovascular, Renal and Metabolic at Boehringer Ingelheim. 'Obesity and MASH are deeply interconnected chronic diseases that no organization can tackle alone.

“长期以来，像MASH这样的严重肝病一直未受到足够关注——但随着MASH发病率在全球肥胖症流行的情况下急剧上升，是时候正面应对肝病了，”勃林格殷格翰心血管、肾脏和代谢治疗领域负责人桑迪·索默表示。“肥胖症和MASH是深度交织的慢性疾病，任何组织都无法单独应对。”

At Boehringer, we're committed to being part of the solution, and the expansion of our partnership with Echosens is one we're particularly excited about. We look forward to working together to drive transformative change in metabolic health for patients, doctors, and healthcare systems worldwide.'.

在勃林格殷格翰，我们致力于成为解决方案的一部分，与Echosens合作关系的扩展让我们感到尤为兴奋。我们期待共同努力，为全球患者、医生和医疗系统带来代谢健康领域的变革性改变。

MASH is a chronic disease that results from excess fat accumulation and inflammation in the liver. It is more common in people living with obesity and, left untreated, can lead to scarring, cirrhosis, and liver failure. Because the disease is often silent in its early stages, it is estimated that fewer than one in five people with MASH are formally diagnosed, underscoring the urgent need for scalable and non-invasive tools to screen these patients and support them with ongoing care..

MASH是一种慢性疾病，是由于肝脏中脂肪过度积累和炎症所导致的。它在肥胖人群中更为常见，如果不加以治疗，可能导致肝硬化、瘢痕形成以及肝功能衰竭。由于该疾病在早期通常没有明显症状，据估计，每五名MASH患者中只有不到一人被正式诊断出来，这突显了对可扩展且非侵入性工具的迫切需求，以筛查这些患者并为其提供持续护理支持。

FibroScan

纤维扫描

, Echosens' non-invasive liver assessment technology, has played a critical role in Boehringer Ingelheim's liver disease research and continues to support two ongoing Survodutide Phase III trials by screening and monitoring patients; as a non-invasive test, FibroScan

，Echosens的无创肝脏评估技术，在勃林格殷格翰的肝病研究中发挥了关键作用，并通过筛选和监测患者继续支持两项正在进行的Survodutide三期试验；作为一种无创检测方法，FibroScan

offers a fast, painless, cost-effective, and scalable alternative to liver biopsy. Survodutide combines

提供了一种快速、无痛、经济高效且可扩展的肝活检替代方案。Survodutide 结合

GLP-1

GLP-1

and glucagon receptor agonists as a novel potential treatment for MASH and associated metabolic conditions like obesity.

并且胰高血糖素受体激动剂作为一种治疗MASH及相关代谢疾病（如肥胖症）的新型潜在疗法。

Survodutide is part of Boehringer Ingelheim's research and development portfolio in the cardiovascular, renal and metabolic disease areas. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally.

Survodutide 是勃林格殷格翰在心血管、肾脏和代谢疾病领域的研发组合的一部分。Survodutide 由 Zealand Pharma 授权给勃林格殷格翰，勃林格殷格翰全权负责全球的开发和商业化。

'We are excited to expand our collaboration with Boehringer Ingelheim, whose innovative approach has the potential to further advance the treatment landscape for MASH,' said

“我们很高兴能够扩大与勃林格殷格翰的合作，他们的创新方法有潜力进一步推进MASH的治疗前景，”

Dominique Legros

多米尼克·勒格罗斯

, CEO of Echosens. 'This partnership reflects our ongoing commitment to support the global liver disease community by enabling smarter clinical trials and broader access to non-invasive diagnostic tools. We are proud to collaborate with Boehringer Ingelheim and welcome them into our shared mission to improve liver health outcomes.'.

Echosens首席执行官表示：“这一合作伙伴关系反映了我们持续致力于支持全球肝病社区，通过实现更智能的临床试验和更广泛的无创诊断工具获取途径。我们很自豪能与勃林格殷格翰合作，并欢迎他们加入我们改善肝脏健康结果的共同使命。”

About Echosens

关于Echosens

Pioneer in its field, Echosens, significantly changed the practice of liver assessment with FibroScan

Echosens作为其领域的先驱，通过FibroScan极大地改变了肝脏评估的实践。

, the non-invasive solution for comprehensive management of liver health. FibroScan

，用于全面管理肝脏健康的非侵入性解决方案。FibroScan

is recognized worldwide and validated by more than 5,384 peer-reviewed publications and 218 international guidelines. Echosens has made FibroScan

在全球范围内得到认可，并由5384篇同行评审的出版物和218项国际指南验证。Echosens 制造了 FibroScan

available in over 127 countries, enabling millions of liver examinations worldwide.

在全球超过127个国家可用，实现了全球范围内数百万次的肝脏检查。

About Boehringer Ingelheim

关于勃林格殷格翰

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain.

勃林格殷格翰是一家活跃于人类和动物健康的生物制药公司。作为行业内在研发领域投资最多的公司之一，该公司专注于在未满足医疗需求的高需求领域开发创新疗法。自1885年成立以来，勃林格始终保持独立，并以长远眼光看待发展，将可持续性贯穿于整个价值链。

More than 54,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow..

超过 54,500 名员工为 130 多个市场服务，共同打造一个更健康、更可持续和更公平的明天。